Niklas Mattsson
Overview
Explore the profile of Niklas Mattsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
177
Citations
12089
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pikwer A, Yang B, Granstrom M, Mattsson N, Sadr-Azodi O
Minerva Anestesiol
. 2022 Oct;
89(1-2):22-31.
PMID: 36282219
Background: In experimental animal studies, exposure to general anesthesia in early childhood may results in changes in infant brain morphology and behavior, potentially leading to the development of autistic behaviors...
2.
Jansen W, Janssen O, Tijms B, Vos S, Ossenkoppele R, Visser P, et al.
JAMA Neurol
. 2022 Jan;
79(3):228-243.
PMID: 35099509
Importance: One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and on positron emission tomography (PET) scans....
3.
Karikari T, Pascoal T, Ashton N, Janelidze S, Benedet A, Rodriguez J, et al.
Lancet Neurol
. 2020 Apr;
19(5):422-433.
PMID: 32333900
Background: CSF and PET biomarkers of amyloid β and tau accurately detect Alzheimer's disease pathology, but the invasiveness, high cost, and poor availability of these detection methods restrict their widespread...
4.
Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey D, et al.
Nat Commun
. 2020 Apr;
11(1):1683.
PMID: 32246036
Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer's disease (AD), reflecting abnormal tau metabolism in the brain. Here we investigate the performance of...
5.
Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach T, Serrano G, et al.
Nat Med
. 2020 Mar;
26(3):379-386.
PMID: 32123385
Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three cohorts, with a...
6.
Obrocki P, Khatun A, Ness D, Senkevich K, Hanrieder J, Capraro F, et al.
Alzheimers Res Ther
. 2020 Mar;
12(1):20.
PMID: 32111242
Until relatively recently, a diagnosis of probable Alzheimer's disease (AD) and other neurodegenerative disorders was principally based on clinical presentation, with post-mortem examination remaining a gold standard for disease confirmation....
7.
Bjurstrom M, Mattsson N, Harsten A, Dietz N, Bodelsson M
Minerva Anestesiol
. 2020 Feb;
86(6):636-644.
PMID: 32013330
Background: Multiple patient and clinical characteristics contribute to the variable outcome of spinal anesthesia (SPA). Acute reduction of cerebrospinal fluid (CSF) volume may alter the effect of SPA. The objective...
8.
Lindh-Rengifo M, Jonasson S, Mattsson N, Ullen S, Nilsson M
Parkinsons Dis
. 2020 Jan;
2019:4747320.
PMID: 31915520
Introduction: Fear of falling (FOF) is more common in people with Parkinson's disease (PD) than in healthy controls. It can lead to several negative consequences such as restrictions in everyday...
9.
Hall S, Janelidze S, Zetterberg H, Brix B, Mattsson N, Surova Y, et al.
Mov Disord
. 2019 Dec;
35(3):513-518.
PMID: 31837067
Background: CSF concentration of neurogranin has been suggested as a biomarker for synapse dysfunction. Objectives: To investigate CSF neurogranin in parkinsonian disorders compared to controls and Alzheimer's disease and the...
10.
Blennow K, Shaw L, Stomrud E, Mattsson N, Toledo J, Buck K, et al.
Sci Rep
. 2019 Dec;
9(1):19024.
PMID: 31836810
We evaluated the performance of CSF biomarkers for predicting risk of clinical decline and conversion to dementia in non-demented patients with cognitive symptoms. CSF samples from patients in two multicentre...